InsiderClue
Stocks · Health care · Medicinal Chemicals & Botanical Products

Regencell Bioscience Holdings Ltd

RGC Clue Score37
Cayman Islands CIK 0001829667
$7.35 -3.67% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $7.35 −66.16% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Jul 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−0.4Net income−0.4Fiscal year 2020Operating income−0.8Net income−0.8EPS, diluted−0.08Fiscal year 2021Operating income−1.4Net income−1.3EPS, diluted−0.13Fiscal year 2022Operating income−7.6Net income−7.4EPS, diluted−0.58Fiscal year 2023Operating income−6.3Net income−5.9EPS, diluted−1.19Fiscal year 2024Operating income−4.7Net income−4.3EPS, diluted−0.87Fiscal year 2025Operating income−3.8Net income−3.6EPS, diluted−0.72Fiscal year 2026Operating income−11.7Net income−11.7EPS, diluted−2.37
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating income −0.4 −0.8 −1.4 −7.6 −6.3 −4.7 −3.8 −11.7
Net income −0.4 −0.8 −1.3 −7.4 −5.9 −4.3 −3.6 −11.7
Growth
EPS, diluted n/a −0.08 −0.13 −0.58 −1.19 −0.87 −0.72 −2.37

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−0.4Fiscal year 2020Operating cash flow−0.7Capital expenditure−0.1Free cash flow−0.8Fiscal year 2021Operating cash flow−0.8Fiscal year 2022Operating cash flow−5.3Capital expenditure−0.8Free cash flow−6.0Fiscal year 2023Operating cash flow−5.0Capital expenditure−0.0Free cash flow−5.0Fiscal year 2024Operating cash flow−4.0Capital expenditure−0.0Free cash flow−4.0Fiscal year 2025Operating cash flow−3.1Capital expenditure−0.2Free cash flow−3.3Fiscal year 2026Operating cash flow−7.7
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −0.4 −0.7 −0.8 −5.3 −5.0 −4.0 −3.1 −7.7
Capital expenditure n/a −0.1 n/a −0.8 −0.0 −0.0 −0.2 n/a
Free cash flow n/a −0.8 n/a −6.0 −5.0 −4.0 −3.3 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash0.2Shareholders’ equity−1.8Fiscal year 2020Cash0.4Shareholders’ equity−2.7Fiscal year 2021Cash0.1Shareholders’ equity−4.0Fiscal year 2022Cash6.4Shareholders’ equity17.1Fiscal year 2023Cash1.6Shareholders’ equity12.0Fiscal year 2024Cash3.0Shareholders’ equity8.2Fiscal year 2025Cash2.4Shareholders’ equity4.9Fiscal year 2026Cash14.2Shareholders’ equity13.3
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 0.2 0.4 0.1 6.4 1.6 3.0 2.4 14.2
Shareholders’ equity −1.8 −2.7 −4.0 17.1 12.0 8.2 4.9 13.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending June, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 30 Jun 2019 FY2020 30 Jun 2020 FY2021 30 Jun 2021 FY2022 30 Jun 2022 FY2023 30 Jun 2023 FY2024 30 Jun 2024 FY2025 30 Jun 2025 FY2026 30 Jun 2026
Returns
n/a n/a n/a −43.6% −48.8% −52.3% −73.7% −87.7%
n/a −158.0% −395.9% −41.3% −46.5% −51.0% −62.3% −79.4%
Balance and payout
n/a 615.7% 1,275.3% 5.2% 5.0% 2.6% 15.6% 9.4%